Eli Lilly Stock (LLY) After Hours Today (Dec. 18, 2025): Orforglipron Headlines, Analyst Forecasts, and What to Watch Before Friday’s Open

Eli Lilly and Company (NYSE: LLY) finished Thursday’s session higher and held those gains in after-hours trading, as investors digested fresh late-stage data for its oral obesity candidate orforglipron—and weighed a second, potentially market-moving theme: pricing pressure and affordability initiatives.

As of early evening after the closing bell, LLY was little changed in after-hours trading at $1,057.26 (+0.04%), after closing the regular session at $1,056.88 (+1.45%). ^[1]

Below is what drove the stock today (Thursday, December 18, 2025)—and what investors should keep on the radar before the market opens Friday, December 19, 2025.

LLY stock price check after the bell

Regular-session close:$1,056.88, up 1.45% on the day
After-hours (early read):$1,057.26, up 0.04% from the close (as of ~5:19 p.m. ET) ^[2]
Intraday range (Thursday): roughly $1,036 to $1,079
Volume: about 3.84 million shares

That steady after-hours tape suggests the day’s biggest information was largely absorbed during regular trading—rather than a new late-breaking announcement hitting after 4 p.m. ET.

The main catalyst today: Lilly’s orforglipron “maintenance” trial results

What Lilly said

Lilly reported positive topline results from ATTAIN-MAINTAIN, a Phase 3 study testing whether a once-daily oral GLP-1 (orforglipron) can help people maintain weight loss after they first lose weight on injectable GLP-1 therapies—including Novo Nordisk’s Wegovy and Lilly’s Zepbound. ^[3]

In Reuters’ summary of the results:

People switching from Wegovy to orforglipron maintained their weight loss with an average weight change of about 0.9 kg (~2 pounds).
People switching from Zepbound to orforglipron maintained their weight loss with an average weight change of about 5 kg (~11 pounds). ^[4]

That “switch strategy” matters because obesity is widely treated as chronic—and long-term adherence to injections can be a barrier for some patients.

Why investors cared

The market takeaway wasn’t simply “another GLP-1 readout.” It was a more specific commercial angle:

Orforglipron as a maintenance off-ramp: Bernstein’s Courtney Breen described it as a potential option for “de-escalating treatment” and improving convenience for chronic maintenance. ^[5]
Oral convenience vs. competitor timing: BMO’s Evan Seigerman argued that convenience may help blunt Novo’s “narrow timeline advantage” in the race to bring an obesity pill to market. ^[6]

Reuters also noted the stock gained as the news crossed, reporting shares up about 1.3% during the session. ^[7]

Safety and “what we still don’t know”

Today’s release was topline. Lilly (and outside analysts) emphasized that more detail is expected later:

The most common side effects were described as mild-to-moderate gastrointestinal, consistent with prior studies. ^[8]
Detailed results are expected at a future medical meeting and in a peer-reviewed publication next year, according to a report summarizing the announcement. ^[9]

For Friday’s open and the next several sessions, watch for any additional clarity on:

discontinuation rates,
subgroup outcomes,
and how “maintenance” was quantified across different estimands and patient baselines (important details that can move sentiment once the full dataset is public). ^[10]

The regulatory angle: FDA timing could be a bigger deal than the headline

One reason today’s readout landed with investors: timing risk is now central to the obesity-pill trade.

Reuters reported:

Lilly and Novo are both awaiting U.S. regulatory decisions for their pills; Novo’s oral Wegovy decision is expected by late December, while Lilly’s orforglipron decision is expected early next year. ^[11]
Lilly received a fast-track voucher in November tied to a Trump administration deal to lower prices for government programs and cash-paying patients. ^[12]
And critically, the FDA could decide on Lilly’s pill as early as March 28 if an accelerated timeline is adopted, Reuters said. ^[13]

That’s not just a calendar curiosity: a materially faster review would change how investors model launch sequencing, market share capture, and competitive response—especially if multiple “next-gen” obesity options converge in 2026.

Today’s forecasts and analyst takes: price targets stayed bullish

Beyond the clinical headline, several analyst notes and consensus updates circulated today, and the overall tone stayed constructive.

From Investing.com’s compiled consensus snapshot:

Consensus rating:Buy (22 Buy, 7 Hold, 1 Sell)
Average 12-month price target:$1,093.22 (about +3.44% upside from the referenced price) ^[14]

And among the firm-level calls dated Dec. 18, 2025:

Goldman Sachs: Buy, $1,145 (maintained)
BMO Capital: Buy/Outperform, $1,200 (maintained)
Leerink Partners: Buy, $1,104 (maintained) ^[15]

Investor’s Business Daily also highlighted the readthrough as a commercial opportunity, citing an analyst view that orforglipron could reach $2 billion in 2026 sales and as much as $16 billion by 2028—well above some prevailing estimates—while noting the stock’s strength near breakout levels. ^[16]

Another big headline today: Lilly is cutting Mounjaro and Zepbound prices in Canada

Not all of today’s Lilly news was about pipeline upside.

Reuters reported that Lilly is reducing prices in Canada for Mounjaro and Zepbound by at least 20%, with changes expected to take effect December 29. Reuters (citing The Globe and Mail) included specific new price points by dose tier. ^[17]

Why this matters for LLY stock

This is a nuanced catalyst:

Bull case: Lower prices can expand access, support volume growth, and potentially reduce political/consumer backlash—especially for high-demand obesity and diabetes drugs.
Bear case: It reinforces the idea that the GLP-1 era is entering a more price-competitive phase, where net pricing and rebates could become a larger swing factor for revenue growth and margins.

With Lilly valued as a premium growth name, anything that changes long-term pricing assumptions can matter almost as much as clinical wins.

The policy backdrop moved today too: drug pricing remains a live issue

Today’s broader healthcare policy headlines also feed into the narrative around GLP-1 affordability and government involvement.

Reuters reported on an AARP analysis suggesting Medicare enrollees could pay materially less out-of-pocket for certain drugs in 2026, tied to negotiated prices under the Inflation Reduction Act framework; it also notes Jardiance (Boehringer Ingelheim and Lilly) is among drugs in the negotiated group. ^[18]
Separately, Reuters reported that Novartis and Roche backed U.S. efforts to lower drug costs and referenced that Lilly and Novo reached a deal last month to slash prices for popular GLP-1 drugs for Medicare/Medicaid and cash payers. ^[19]

For Lilly shareholders, these stories reinforce a key point going into Friday: policy and pricing headlines can swing sentiment quickly, even when the company-specific pipeline news is strong.

What to know before the market opens tomorrow (Friday, Dec. 19, 2025)

Here are the most practical, near-term items that could influence LLY at the open and through Friday’s session:

1) Watch for follow-on analyst notes and upgrades

Today already delivered a stack of reaffirmations and targets. The next wave is often:

“second-day” commentary,
deeper valuation notes,
and competitive scenario modeling (especially around Novo’s expected oral Wegovy decision by late December). ^[20]

2) Track any FDA timeline signals on orforglipron

The market is likely to react to process signals (voucher mechanics, official review timelines, acceptance milestones) nearly as much as to the topline efficacy language. Reuters’ mention of a possible March 28 decision date is a particularly sharp “watch item” for traders. ^[21]

3) Pricing headlines could keep coming

Between:

Canada price cuts (Mounjaro/Zepbound), ^[22]
ongoing U.S. “lower drug costs” negotiations, ^[23]
and Medicare-related reporting, ^[24]
the risk is not just what Lilly does—but what the policy environment signals about where GLP-1 net pricing goes next.

4) Friday is a major options-expiration day

December 19, 2025 is a quadruple witching date (a day when multiple major derivatives contracts expire), which can increase volume and volatility—sometimes especially in widely held large-cap names. ^[25]

This doesn’t dictate direction, but it can amplify moves around key price levels—particularly for a high-dollar stock like LLY.

5) Key levels traders will be watching

Without turning this into a trading manual, the tape gives a few obvious reference points:

Thursday’s intraday high area near $1,079 (potential resistance)
The $1,040-ish zone (near Thursday’s lows / recent closes) as a potential support area ^[26]

And with the stock within striking distance of its upper 52-week zone (per widely reported ranges), any strong premarket catalyst can quickly turn “range day” into “breakout attempt.” ^[27]

Bottom line for LLY stock heading into Friday

Eli Lilly stock’s after-hours stability masks a genuinely important day of information flow:

The orforglipron maintenance data strengthens the bull narrative that Lilly can participate across the full obesity “patient lifecycle”—from induction weight loss (injections) to longer-term maintenance (a pill). ^[28]
Analyst forecasts stayed broadly bullish today, with multiple firms maintaining targets and consensus still pointing to a Buy stance. ^[29]
At the same time, pricing actions (Canada cuts) and policy headlines keep reminding investors that GLP-1 success increasingly lives at the intersection of clinical data, manufacturing scale, and affordability. ^[30]